title: Complex management of resistant oral herpes simplex virus infection following hematopoietic stem cell transplantation: potential role of topical cidofovir.
abstract: Herpes simplex virus (HSV) infection commonly occurs during the immunosuppression associated with hematopoietic stem cell transplantation (HSCT). Prophylaxis of recurrent infection and management of clinical infection have relied upon acyclovir and congeners. More recently, resistant HSV infection is seen in HSCT and presents new challenges in management. We present a case of HSV following HSCT that provided effective symptomatic management.
  
  
  
  Oral symptoms and lesions were repeatedly reduced when topical cidofovir was used, strongly supporting the effect of cidofovir used in a host who could not tolerate systemic antiviral medications.
  
  
  
  Topical cidofovir can provide effective management of symptomatic oropharyngeal HSV while reducing risk of systemic toxicity and drug interaction and represents an additional approach to management for management in medically compromised patients.
authors.affiliation: Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. joel.epstein@cshs.org.|Cedars-Sinai Health System, Los Angeles, CA, USA. joel.epstein@cshs.org.
authors.forename: Joel B
authors.initials: JB
authors.lastname: Epstein
authors.affiliation: Cedars-Sinai Health System, Los Angeles, CA, USA.
authors.forename: Sara
authors.initials: S
authors.lastname: Gharapetian
authors.affiliation: Cedars-Sinai Health System, Los Angeles, CA, USA.
authors.forename: Ali R
authors.initials: AR
authors.lastname: Rejali
authors.affiliation: Cedars-Sinai Health System, Los Angeles, CA, USA.
authors.forename: Rachel
authors.initials: R
authors.lastname: Zabner
authors.affiliation: Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.|Cedars-Sinai Health System, Los Angeles, CA, USA.|Blood and Marrow Transplant Program, University of California, San Diego, San Diego, CA, USA.
authors.forename: Michael
authors.initials: M
authors.lastname: Lill
authors.affiliation: Blood and Marrow Transplant Program, University of California, San Diego, San Diego, CA, USA.
authors.forename: Dimitrios
authors.initials: D
authors.lastname: Tzachanis
mesh_terms: D000287:Administration, Topical; D000368:Aged; D000998:Antiviral Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000077404:Cidofovir; D003596:Cytosine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006561:Herpes Simplex / Q000628:therapy* / Q000821:virology; D006801:Humans; D008297:Male; D063065:Organophosphonates / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D019172:Transplantation Conditioning / Q000009:adverse effects*
chemical_list: D000998:Antiviral Agents; D063065:Organophosphonates; D003596:Cytosine; D000077404:Cidofovir
keywords: Acyclovir resistant herpes simplex virus infection; Hematopoietic stem cell transplantation; Topical cidofovir